Larisa Rudenko1, Irina Isakova-Sivak2, Anatoly Naykhin1, Irina Kiseleva1, Marina Stukova3, Mariana Erofeeva4, Daniil Korenkov1, Victoria Matyushenko1, Erin Sparrow5, Marie-Paule Kieny6. 1. Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russia. 2. Department of Virology, Institute of Experimental Medicine, Saint Petersburg, Russia. Electronic address: isakova.sivak@gmail.com. 3. Department of Molecular Virology, Research Institute of Influenza, Saint Petersburg, Russia. 4. Department of Epidemiology and Prophylaxis, Research Institute of Influenza, Saint Petersburg, Russia. 5. Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland. 6. Department of Health Systems and Innovation, World Health Organization, Geneva, Switzerland.
Abstract
BACKGROUND: H7N9 avian influenza viruses characterised by high virulence and presence of mammalian adaptation markers have pandemic potential. Specific influenza vaccines remain the main defence. We assessed the safety and immunogenicity of an H7N9 live attenuated influenza vaccine (LAIV) candidate in healthy adult volunteers. METHODS: We did a phase 1, double-blind, randomised, placebo-controlled trial in Saint Petersburg, Russia. Eligible participants were healthy adults aged 18-49 years. The participants were randomised 3:1 to receive live vaccine or placebo, according to a computer-generated randomisation scheme. Two doses of vaccine or placebo were administered intranasally 28 days apart, each followed by 7 day stays in hospital. Immune responses were assessed in nasal swabs, saliva, and serum specimens collected before and 28 days after each vaccine dose. The primary outcome was the safety profile. This trial is registered with ClinicalTrials.gov, number NCT02480101. FINDINGS: Between Oct 21, 2014, and Oct 31, 2014, 40 adults were randomised, of whom 39 (98%) were included in the per-protocol analysis (29 in the vaccine group and ten in the placebo group). The frequency of adverse events did not differ between the vaccine and placebo groups. Seroconversion of neutralising antibodies was seen in 14 participants after the first vaccine dose (48%, 95% CI 29·4-67·5) and 21 after the second vaccine dose (72%, 52·8-87·3). Immune responses were seen in 27 of 29 recipients (93%, 95% CI 77·2-99·2). Adverse effects were seen in 19 (63%) vaccine recipients and nine (90%) placebo recipients after the first dose and in nine (31%) and four (40%), respectively, after the second dose. These effects were mainly local and all were mild. INTERPRETATION: The H7N9 LAIV was well tolerated and safe and showed good immunogenicity. FUNDING: WHO.
BACKGROUND: H7N9 avian influenza viruses characterised by high virulence and presence of mammalian adaptation markers have pandemic potential. Specific influenza vaccines remain the main defence. We assessed the safety and immunogenicity of an H7N9 live attenuated influenza vaccine (LAIV) candidate in healthy adult volunteers. METHODS: We did a phase 1, double-blind, randomised, placebo-controlled trial in Saint Petersburg, Russia. Eligible participants were healthy adults aged 18-49 years. The participants were randomised 3:1 to receive live vaccine or placebo, according to a computer-generated randomisation scheme. Two doses of vaccine or placebo were administered intranasally 28 days apart, each followed by 7 day stays in hospital. Immune responses were assessed in nasal swabs, saliva, and serum specimens collected before and 28 days after each vaccine dose. The primary outcome was the safety profile. This trial is registered with ClinicalTrials.gov, number NCT02480101. FINDINGS: Between Oct 21, 2014, and Oct 31, 2014, 40 adults were randomised, of whom 39 (98%) were included in the per-protocol analysis (29 in the vaccine group and ten in the placebo group). The frequency of adverse events did not differ between the vaccine and placebo groups. Seroconversion of neutralising antibodies was seen in 14 participants after the first vaccine dose (48%, 95% CI 29·4-67·5) and 21 after the second vaccine dose (72%, 52·8-87·3). Immune responses were seen in 27 of 29 recipients (93%, 95% CI 77·2-99·2). Adverse effects were seen in 19 (63%) vaccine recipients and nine (90%) placebo recipients after the first dose and in nine (31%) and four (40%), respectively, after the second dose. These effects were mainly local and all were mild. INTERPRETATION: The H7N9 LAIV was well tolerated and safe and showed good immunogenicity. FUNDING: WHO.
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: L G Rudenko; A N Slepushkin; A S Monto; A P Kendal; E P Grigorieva; E P Burtseva; A R Rekstin; A L Beljaev; V E Bragina; N Cox Journal: J Infect Dis Date: 1993-10 Impact factor: 5.226
Authors: Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes Journal: NPJ Vaccines Date: 2020-05-11 Impact factor: 7.344
Authors: Sinthujan Jegaskanda; Mary Dawn T Co; John Cruz; Kanta Subbarao; Francis A Ennis; Masanori Terajima Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Patricia Winokur; Hana M El Sahly; Mark J Mulligan; Sharon E Frey; Richard Rupp; Evan J Anderson; Kathryn M Edwards; David I Bernstein; Kenneth Schmader; Lisa A Jackson; Wilbur H Chen; Heather Hill; Abigail Bellamy Journal: Vaccine Date: 2021-01-21 Impact factor: 3.641
Authors: Leonard Moise; Bethany M Biron; Christine M Boyle; Nese Kurt Yilmaz; Hyesun Jang; Celia Schiffer; Ted M Ross; William D Martin; Anne S De Groot Journal: Hum Vaccin Immunother Date: 2018-09-05 Impact factor: 3.452